Synopsis
Recognise pulmonary and multisystem sarcoidosis, secure proportionate diagnostic evidence and treat only when organ threat, disability or unacceptable quality-of-life loss justifies risk.
- Sarcoidosis is a multisystem granulomatous disorder of uncertain cause; pulmonary involvement is common but symptoms and organ risk vary widely.
- Bilateral hilar and mediastinal lymphadenopathy, perilymphatic nodules and upper-zone fibrosis are characteristic imaging patterns, not independently diagnostic findings.
- Many patients with typical, non-threatening disease improve spontaneously and do not need systemic treatment.
- Treatment has two broad indications: prevention of death or irreversible organ disability, and relief of symptoms that materially impair quality of life.
- A tissue diagnosis should show non-caseating granulomas from the safest useful site, while infection, exposure-related granulomatous disease and malignancy are excluded.
- A highly typical presentation such as Löfgren syndrome may be managed without biopsy after specialist review when alternative disease is unlikely.
- Serum ACE lacks adequate sensitivity and specificity for diagnosis or routine treatment decisions; it must never replace clinical synthesis.
- Ask every patient about palpitations, presyncope, syncope, chest pain, visual symptoms and neurological change because these may reveal high-risk organ involvement.
- Check calcium and renal function, and avoid uncritical vitamin D or calcium supplementation because sarcoid granulomas can increase active vitamin D production.
- Pulmonary monitoring relies on symptoms, chest imaging and serial physiology; radiographic stage alone does not determine functional severity or need for therapy.
Key red flags
Unexplained syncope or presyncope, persistent palpitations, conduction block, ventricular arrhythmia or new heart failure may indicate cardiac sarcoidosis and requires urgent specialist evaluation.
Painful red eye, photophobia, reduced vision, facial weakness, neuropathy, seizures, pituitary symptoms or meningeal features demand rapid organ-specific assessment because delay risks irreversible disability.
Thirst, polyuria, constipation, confusion, nephrolithiasis or renal dysfunction may reflect disordered calcium metabolism and should prompt urgent biochemical assessment when severe.
Investigation priorities
Define thoracic distribution and select a safe diagnostic site.
Management branches
Imaging and clinical findings suggest pulmonary sarcoidosis.
- Assess severity and ask deliberately about cardiac, eye and neurological red flags, exposures, travel, immune status, constitutional symptoms and medicines.
- Review chest imaging with thoracic radiology, obtain physiology and baseline blood tests, then decide whether the presentation is sufficiently typical for observation without biopsy.
- When tissue is needed, sample the safest accessible site or use EBUS for thoracic nodes, requesting microbiological exclusion of infection as well as histology.
- Record diagnostic confidence and alternative diagnoses; reconsider lymphoma, tuberculosis, fungal infection, berylliosis and silicosis when the course or imaging is atypical.